Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Detection of the High-Level Aminoglycoside Resistance Gene aph(2")-Ib in Enterococcus faecium

Susan J. Kao, Il You, Don B. Clewell, Susan M. Donabedian, Marcus J. Zervos, Joanne Petrin, Karen J. Shaw, Joseph W. Chow
Susan J. Kao
Research and Medical Service, John D. Dingell VA Medical Center, and Wayne State University School of Medicine, Detroit, Michigan 48201;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Il You
Research and Medical Service, John D. Dingell VA Medical Center, and Wayne State University School of Medicine, Detroit, Michigan 48201;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Don B. Clewell
Departments of Biologic and Materials Sciences and Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan 48109;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan M. Donabedian
William Beaumont Hospital, Royal Oak, Michigan 48073; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus J. Zervos
William Beaumont Hospital, Royal Oak, Michigan 48073; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanne Petrin
Schering-Plough Research Institute, Kenilworth, New Jersey 07033
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen J. Shaw
Schering-Plough Research Institute, Kenilworth, New Jersey 07033
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph W. Chow
Research and Medical Service, John D. Dingell VA Medical Center, and Wayne State University School of Medicine, Detroit, Michigan 48201;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.44.10.2876-2879.2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A new high-level gentamicin resistance gene, designatedaph(2")-Ib, was cloned from Enterococcus faecium SF11770. The deduced amino acid sequence of the 897-bp open reading frame of aph(2")-Ib shares homology with the aminoglycoside-modifying enzymes AAC(6′)-APH(2"), APH(2")-Ic, and APH(2")-Id. The observed phosphotransferase activity is designated APH(2")-Ib.

High-level gentamicin resistance (MIC ≥ 500 μg/ml) in enterococci is predominantly mediated byaac(6′)-Ie-aph(2")-Ia, which encodes the bifunctional aminoglycoside-modifying enzyme AAC(6′)-APH(2") (10). Found less commonly is aph(2")-Id, another gene recently reported to be associated with high-level gentamicin resistance in enterococci (19). The presence of high-level gentamicin resistance in enterococci eliminates the synergistic killing usually seen when gentamicin is combined with a cell wall-active agent, such as ampicillin or vancomycin. aph(2")-Ic is a mid-level gentamicin resistance gene isolated infrequently from enterococci that eliminates the synergism between ampicillin and gentamicin, even though the gentamicin MIC for strains containing this gene is typically only ca. 256 μg/ml (4). We describe the cloning and sequencing of another aminoglycoside resistance gene, aph(2")-Ib, that is associated with high-level gentamicin resistance inEnterococcus faecium.

(This work was presented in part at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 28 September to 1 October 1997.)

Enterococci were identified by conventional biochemical criteria (9). E. faecium SF11770 is a blood culture isolate from a patient in Detroit, Mich. Escherichia coli DH5α and E. coli DH10b were used as recipients for electroporation and as hosts for maintaining recombinant plasmids.E. faecium GE1 (8) and Enterococcus faecalis FA2-2 (5) were the recipient strains in mating experiments. Gentamicin was obtained from Fluka (Buchs, Switzerland). Arbekacin and netilmicin were provided by Meiji Seika Kaisha (Tokyo, Japan). All other antimicrobial agents were purchased from Sigma Chemical Company (St. Louis, Mo.). Antimicrobial susceptibilities were determined by a standard broth microdilution method (15). Tests of synergistic killing were performed using a previously described method (12), with some modifications. Synergy was defined as a ≥2-log10 decrease in CFU/ml between the combination and its most active constituent after 24 h, with the number of surviving organisms in the presence of the combination being ≥2 log10 CFU/ml below the number of organisms in the starting inoculum. Also, at least one of the drugs must be present in a concentration that does not affect the growth curve of the test organism when used alone. One hundred twenty-one enterococcal clinical isolates (78 E. faecalis, 41 E. faecium, 1Enterococcus raffinosus, and 1 Enterococcus gallinarum isolate) with high-level gentamicin resistance from separate patients in six Detroit, Mich., area hospitals were used to screen for the presence of the new gene. This collection included isolates that were part of clonal outbreaks in the Detroit area and had been previously screened for aph(2")-Id (19).

Plasmid DNA minipreparations and total genomic DNA were obtained by a modified alkaline lysis method (20). Methods for restriction endonuclease digestion, agarose gel electrophoresis of DNA, transformation by using calcium chloride or electroporation, and Southern blot hybridization were performed as previously described (2, 7, 19). The phosphocellulose paper binding assay was performed as previously described (4, 17). Oligonucleotide primers were synthesized by GIBCO BRL Life Technologies (Gaithersburg, Md.). The probes for aac(6′)-Ie-aph(2")-Ia,aph(2")-Ic, and aph(2")-Id were prepared as described previously (4, 10, 19). DNA to be sequenced was obtained as described in the Qiagen (Chatsworth, Calif.) plasmid handbook. The vectors pBluescript II KS(+) (Stratagene Cloning Systems, La Jolla, Calif.) and pMW119 (Nippon Gene Corporation, Toyama, Japan) were used in standard cloning experiments (2). Nucleotide sequencing was performed at the DNA Sequencing Core, University of Michigan, Ann Arbor. Computer analysis was performed with MacVector software, version 6.0, and AssemblyLIGN, version 1.0.9 (Oxford Molecular Group, Oxford, United Kingdom). The GenBank database was searched with the BLAST program from the National Center for Biotechnology Information (1). Amino acid sequences were compared by using the Gap Analysis Program from the University of Wisconsin Genetics Computer Group (6). The PCR primers used for detecting the aac(6′)-Ie-aph(2")-Ia gene were 5′-GAGCAATAAGGGCATACCAAAAATC-3′ and 5′-CCGTGCATTTGTCTTAAAAAACTGG-3′. The primers for detectingaph(2")-Ib were 5′-TATGGATCCATGGTTAACTTGGACGCTGAG-3′ and 5′-AT TAAGCTTCCTGCTAAAATATAAACATCTCTGCT-3′. The primers for detecting aph(2")-Ic were as previously reported (4). The primers for detecting aph(2")-Id were 5′-GGTGGTTTTTACAGGAATGCCATC-3′ and 5′-CCCTCTTCATACCAATCCATATAACC-3′.

Aminoglycoside MICs for E. faecium SF11770 are shown in Table 1. The ampicillin MIC was 128 μg/ml, the streptomycin MIC was >2,000 μg/ml, and the vancomycin MIC was >256 μg/ml. The probes for theaac(6′)-Ie-aph(2")-Ia, aph(2")-Ic, andaph(2")-Id genes did not hybridize to Southern blots of total cellular DNA from E. faecium SF11770. Filter matings, with SF11770 as the donor and E. faecium GE1 or E. faecalis FA2-2 as the recipient, did not result in the transfer of gentamicin resistance (the frequency was <1 × 10−9per recipient CFU). Electroporation of a plasmid preparation from SF11770 into competent E. faecalis OG1RF cells also did not result in the selection of gentamicin-resistant transformants. In tests of bactericidal synergistic killing against E. faeciumSF11770, ampicillin at 64 μg/ml combined with arbekacin at 8 or 16 μg/ml produced a 3- to 4-log10 decrease in CFU per milliliter at 24 h compared to the most active agent (ampicillin) (Fig. 1A and B). However, since the growth curve of the organism with either ampicillin or arbekacin alone was slightly different than the growth with no antimicrobial agent, this did not fulfill the strict criteria for synergistic killing. Ampicillin at 64 μg/ml combined with arbekacin at 2 or 4 μg/ml did not produce greater killing at 24 h than either drug alone (Fig.1A and C). The combination of ampicillin (64 μg/ml) and gentamicin (16 μg/ml) also did not produce greater killing at 24 h than either drug alone (Fig. 1D).

View this table:
  • View inline
  • View popup
Table 1.

Susceptibilities of E. faecium SF11770,E. coli KHE5-2, and E. coli DH10b(pMW119) to aminoglycosides

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Tests of synergistic killing against E. faecium SF11770. ●, no antimicrobial; ○, ampicillin (64 μg/ml); ▾, arbekacin (16 μg/ml); ▿, ampicillin (64 μg/ml) plus arbekacin (16 μg/ml); ■, arbekacin (8 μg/ml); □, ampicillin (64 μg/ml) plus arbekacin (8 μg/ml); ⧫, arbekacin (4 μg/ml); ◊, ampicillin (64 μg/ml) plus arbekacin (4 μg/ml); ▴, arbekacin (2 μg/ml); ▵, ampicillin (64 μg/ml) plus arbekacin (2 μg/ml); ⬢, gentamicin (16 μg/ml); and ⬡, ampicillin (64 μg/ml) plus gentamicin (16 μg/ml).

Partial Sau3AI digestions of total genomic DNA from SF11770 were ligated to pBluescript II KS(+) digested with BamHI and dephosphorylated with calf intestine alkaline phosphatase. After electroporation of the ligated products, selection on Luria-Bertani plates containing 25 μg of gentamicin per ml yielded small numbers of gentamicin-resistant E. coli DH5α transformants. Additional subcloning experiments using HindIII andEcoRI and the low-copy-number vector pMW119 yielded a gentamicin-resistant E. coli DH10b transformant, designated KHE5-2, which contained a 1.5-kb cloned fragment. Aminoglycoside MICs for E. coli KHE5-2 and E. coli DH10b(pMW119) are shown in Table 1.

Nucleotide sequencing of the 1.5-kb fragment revealed the presence of an 897-bp open reading frame, with a G+C content of 32%, whose predicted amino acid sequence showed homology with sequences of aminoglycoside phosphotransferases deposited in GenBank. The highest homology was seen with the deduced proteins from theaph(2")-Id (32% identity and 49% similarity) andaac(6′)-Ie-aph(2")-Ia genes (33% identity and 51% similarity with the APH(2")-Ia domain). Less closely related was theaph(2")-Ic gene (25% identity and 44% similarity). The gentamicin resistance gene has been designated aph(2")-Ib. The aminoglycoside phosphotransferase activity, designated APH(2")-Ib, was confirmed by the phosphocellulose paper binding assay. Crude extracts from E. coli KHE5-2 exhibited phosphotransferase activity with all of the aminoglycoside substrates listed in Table 1, except for neomycin. aph(2")-Ib was cloned by PCR into the shuttle vector pWM401 (20), the recombinant DNA was electroporated into competent E. faecalis JH2-2 cells (gentamicin MIC = 16 μg/ml), and high-level gentamicin-resistant (MIC > 2,000 μg/ml) E. faecalis transformants were obtained.

Evaluation of the presence of gentamicin resistance genes by PCR showed that 6 of 121 isolates (5%) were negative for theaac(6′)-Ie-aph(2")-Ia, aph(2")-Ic, andaph(2")-Id genes. All six were positive for theaph(2")-Ib gene by PCR. These six isolates (five from blood and one from stool cultures) were all vancomycin-resistant E. faecium from three hospitals in Detroit, Mich., and five belonged to the same clonal group, as determined by pulsed-field gel electrophoresis. The gentamicin MICs for all six were ≥1,024 μg/ml, and the arbekacin MICs ranged from 8 to 32 μg/ml. All of the 121 isolates possessed one of the four gentamicin resistance genes tested, and none possessed more than one of the genes tested.

aph(2")-Ib is now the fourth aminoglycoside resistance gene detected in Enterococcus spp. that eliminates the bactericidal synergistic effect of ampicillin and gentamicin against enterococci. The origin of the aph(2")-I family of genes remains uncertain. aac(6′)-Ie-aph(2")-Ia is also found in staphylococci and streptococci (18; M. Galimand, G. Gerbaud, P. Courvalin, and T. Lambert, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 833, 1999), and it has been proposed that aac(6′)-Ie-aph(2")-Ia was transmitted initially from staphylococci to enterococci (14). However,aph(2")-Ib, aph(2")-Ic, and aph(2")-Idhave not yet been detected in staphylococci and thus are less likely to have been transmitted from staphylococci (21). When we compared the nucleic acid sequence of aph(2")-Ib to that of an unpublished aph(2") resistance gene from an E. coli clinical isolate from the former republic of Czechoslovakia (J. Petrin, R. Kuvelkar, M. Kettner, R. S. Hare, G. H. Miller, and K. J. Shaw, Cold Spring Harbor Bacteria Phage Meet., abstr. 197, 1995), we found that the two sequences were identical, except for four nucleotides (resulting in three amino acid changes). The 32% G+C content of aph(2")-Ib raises the possibility that this gene may have first originated in enterococci and then been transmitted to E. coli, since the G+C contents ofEnterococcus spp. and E. coli are approximately 35 and 50%, respectively.

The aminoglycoside MIC profile of E. faecium SF11770 indicates various degrees of resistance to most of the clinically available aminoglycosides, except for arbekacin (Table 1). Arbekacin is a new aminoglycoside available in Japan, where it is used to treat gentamicin- and methicillin-resistant staphylococci (11, 13, 16). Although the combination of ampicillin and arbekacin at achievable concentrations in serum did not strictly fulfill the criteria for synergism against E. faecium SF11770, the combination with higher arbekacin concentrations did exhibit significantly greater killing of the organism than either agent alone. These preliminary findings need to be confirmed by in vivo data before arbekacin can be recommended for use in combination therapy against enterococci that possess aph(2")-Ib.

Nucleotide sequence accession number.The nucleotide sequence for aph(2")-Ib has been deposited in GenBank under accession number AF207840.

ACKNOWLEDGMENTS

This study was supported in part by the Department of Veterans' Affairs.

We thank Haruyoshi Tomita, Stephen A. Lerner, and Sergei Vakulenko for helpful discussions, Liberty Chow for technical assistance, and Glenn W. Kaatz for help with Fig. 1.

FOOTNOTES

    • Received 22 December 1999.
    • Returned for modification 6 March 2000.
    • Accepted 17 July 2000.
  • Copyright © 2000 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Altschul S. F.,
    2. Gish W.,
    3. Miller W.,
    4. Myers E. W.,
    5. Lipman D. J.
    Basic local alignment search tool. J. Mol. Biol. 215 1990 403 410
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Ausubel F. M.,
    2. Brent R.,
    3. Kingston R. E.,
    4. Moore D. D.,
    5. Seidman J. G.,
    6. Smith J. A.,
    7. Struhl K.
    Current protocols in molecular biology 1 1995 John Wiley & Sons, Inc. New York, N.Y
  3. 3.
    1. Chow J. W.,
    2. Donabedian S. M.,
    3. Clewell D. B.,
    4. Sahm D. F.,
    5. Zervos M. J.
    In vitro susceptibility and molecular analysis of gentamicin-resistant enterococci. Diagn. Microbiol. Infect. Dis. 32 1998 141 146
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Chow J. W.,
    2. Zervos M. J.,
    3. Lerner S. A.,
    4. Thal L. A.,
    5. Donabedian S. M.,
    6. Jaworski D. D.,
    7. Tsai S.,
    8. Shaw K. J.,
    9. Clewell D. B.
    A novel gentamicin resistance gene in Enterococcus. Antimicrob. Agents Chemother. 41 1997 511 514
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Clewell D. B.,
    2. Tomich P. K.,
    3. Gawron-Burke M. C.,
    4. Franke A. E.,
    5. Yagi Y.,
    6. An F. Y.
    Mapping of Streptococcus faecalis plasmids pAD1 and pAD2 and studies relating to transposition of Tn917. J. Bacteriol. 152 1982 1220 1230
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Devereux J.,
    2. Haeberli P.,
    3. Smithies O.
    A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res. 12 1984 387 395
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Donabedian S.,
    2. Chow J. W.,
    3. Shlaes D. M.,
    4. Green M.,
    5. Zervos M. J.
    DNA hybridization and contour-clamped homogeneous electric field electrophoresis for identification of enterococci to the species level. J. Clin. Microbiol. 33 1995 141 145
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Eliopoulos G. M.,
    2. Wennersten C.,
    3. Zighelboim-Daum S.,
    4. Reiszner E.,
    5. Goldmann D.,
    6. Moellering R. C. Jr.
    High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob. Agents Chemother. 32 1988 1528 1532
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Facklam R. R.,
    2. Collins M. D.
    Identification of Enterococcus species isolated from human infections by a conventional test scheme. J. Clin. Microbiol. 27 1989 731 734
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Ferretti J. J.,
    2. Gilmore K. S.,
    3. Courvalin P.
    Nucleotide sequence analysis of the gene specifying the bifunctional 6′-aminoglycoside acetyltransferase 2"-aminoglycoside phosphotransferase enzyme in Streptococcus faecalis and identification and cloning of gene regions specifying the two activities. J. Bacteriol. 167 1986 631 638
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Hotta K.,
    2. Zhu C. B.,
    3. Ogata T.,
    4. Sunada A.,
    5. Ishikawa J.,
    6. Mizuno S.
    Enzymatic 2"-N-acetylation of arbekacin and antibiotic activity of its product. J. Antibiot. 49 1996 458 464
    OpenUrlPubMed
  12. 12.↵
    1. Knapp C.,
    2. Moody J. A.
    Tests to assess bactericidal activity. Part 3. Time-kill assay for determining synergy Clinical microbiology procedures handbook Isenberg H. D. 1 1992 5.16.21 5.16.29 American Society for Microbiology Washington, D.C.
    OpenUrl
  13. 13.↵
    1. Kondo S.,
    2. Tamura A.,
    3. Gomi S.,
    4. Ikeda Y.,
    5. Takeuchi T.,
    6. Mitsuhashi S.
    Structures of enzymatically modified products of arbekacin by methicillin-resistant Staphylococcus aureus. J. Antibiot. 46 1993 310 315
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Murray B. E.
    Diversity among multidrug-resistant enterococci. Emerg. Infect. Dis. 4 1998 37 47
    OpenUrlPubMedWeb of Science
  15. 15.↵
    National Committee for Clinical Laboratory Standards Approved standard M7-A4. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 4th ed. 1997 National Committee for Clinical Laboratory Standards Wayne, Pa
  16. 16.↵
    1. Osakabe Y.,
    2. Takahashi Y.,
    3. Narihara K.
    The utility and dosage and administration of arbekacin in patients with MRSA infection. Antibiot. Chemother. 12 1996 120 127
    OpenUrl
  17. 17.↵
    1. Perlin M. H.,
    2. Lerner S. A.
    Amikacin resistance associated with a plasmid-borne aminoglycoside phosphotransferase in Escherichia coli. Antimicrob. Agents Chemother. 16 1979 598 604
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Rouch D. A.,
    2. Byrne M. E.,
    3. Kong Y. C.,
    4. Skurray R. A.
    The aacA-aphD gentamicin and kanamycin resistance determinant of Tn4001 from Staphylococcus aureus: expression and sequence analysis. J. Gen. Microbiol. 133 1987 817 822
    OpenUrl
  19. 19.↵
    1. Tsai S. F.,
    2. Zervos M. J.,
    3. Clewell D. B.,
    4. Donabedian S. M.,
    5. Sahm D. F.,
    6. Chow J. W.
    A new high-level gentamicin resistance gene, aph(2")-Id, in Enterococcus spp. Antimicrob. Agents Chemother. 42 1998 1229 1232
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Wirth R.,
    2. An F. Y.,
    3. Clewell D. B.
    Highly efficient protoplast transformation system for Streptococcus faecalis and a new Escherichia coli- S. faecalis shuttle vector. J. Bacteriol. 165 1986 831 836
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. You I.,
    2. Kariyama R.,
    3. Zervos M. J.,
    4. Kumon H.,
    5. Chow J. W.
    In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 36 2000 37 41
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Detection of the High-Level Aminoglycoside Resistance Gene aph(2")-Ib in Enterococcus faecium
Susan J. Kao, Il You, Don B. Clewell, Susan M. Donabedian, Marcus J. Zervos, Joanne Petrin, Karen J. Shaw, Joseph W. Chow
Antimicrobial Agents and Chemotherapy Oct 2000, 44 (10) 2876-2879; DOI: 10.1128/AAC.44.10.2876-2879.2000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Detection of the High-Level Aminoglycoside Resistance Gene aph(2")-Ib in Enterococcus faecium
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Detection of the High-Level Aminoglycoside Resistance Gene aph(2")-Ib in Enterococcus faecium
Susan J. Kao, Il You, Don B. Clewell, Susan M. Donabedian, Marcus J. Zervos, Joanne Petrin, Karen J. Shaw, Joseph W. Chow
Antimicrobial Agents and Chemotherapy Oct 2000, 44 (10) 2876-2879; DOI: 10.1128/AAC.44.10.2876-2879.2000
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Bacterial Proteins
Enterococcus faecium
Phosphotransferases (Alcohol Group Acceptor)

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596